Human Thrombomodulin/BDCA-3 Biotinylated Antibody

Catalog #: BAM39471 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
BAM39471

Product Details

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Thrombomodulin/BDCA-3 Biotinylated Antibody Summary

Species Reactivity

Human

Specificity

Detects human Thrombomodulin in ELISAs. In sandwhich immunoassays, no cross-reactivity or interference with recombinant mouse Thrombomodulin, recombinant human Coagulation Factor II, VII, X, or XI is observed.

Source

Monoclonal Mouse IgG_2A Clone # 501727

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Thrombomodulin/BDCA-3
Ala19-Ser515
Accession # P07204

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Label

Biotin

Applications

Recommended Concentration

Sample

Human Thrombomodulin/BDCA-3 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Detection (Matched Antibody Pair)

0.5-2.0 µg/mL

Use in combination with:

Capture Reagent: Human Thrombomodulin/BDCA‑3 Antibody (Catalog # MAB3947)

Standard: Recombinant Human Thrombomodulin/BDCA-3 Protein, CF (Catalog # 3947-PA)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Thrombomodulin/BDCA-3

Encoded by the THBD gene, Thrombomodulin is also known as CD141 antigen and blood dendritic cell antigen 3 (BDCA-3). The deduced amino acid (aa) sequence of human THBD (Accession # P07204) predicts a signal peptide (aa 1 - 18) and a mature chain (aa 19 - 575) that consists of following domains: C‑type lectin (aa 31 - 169), EGF-like (aa 241 - 281, aa 284 - 324, aa 325 - 363, aa 365 ‑ 405, aa 404 - 440, and aa 441 - 481), transmembrane (aa 516 to 539) and cytoplasmic (aa 540 ‑ 575). The R&D Systems rhTHBD consists of aa 19 - 515, corresponding to the extracellular portion of the type I membrane protein. Predominantly synthesized by vascular endothelial cells, THBD inhibits coagulation and fibrinolysis (1 ‑ 3). It functions as a cell surface receptor and an essential cofactor for active thrombin, which in turn activates protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), also known as carboxypeptidase B2 (CPB2). Activated protein C (APC), facilitated by protein S, degrades coagulation factors Va and VIIIa, which are required for thrombin activation. Activated CPB2 cleaves basic C‑terminal aa residues of its substrates, including fibrin, preventing the conversion of plasminogen to plasmin. In addition, THBD gene polymorphisims are associated with human disease and THBD plays a role in thrombosis, stroke, arteriosclerosis, and cancer (4). For example, increased serum levels of THBD, due to protease cleavage, have been associated with smoking, cardiac surgery, atherosclerosis, liver cirrhosis, diabetes mellitus, cerebral and myocardial infarction, and multiple sclerosis (5).

References